Orphanet: Studio di fase 2 con RDHAP bortezomib nella terapia di induzione pre consolidamento ad alte dosi e trapianto autologo di cellule staminali in linfomi diffusi a grandi cellule B recidivati refrattari : BR DHAP ASCT versus R DHAP ASCT
x

Search for a clinical trial

* (*) mandatory field

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : National
  • Sponsor : Fondazione italiana linfomi onlus
    • Phase : II
  • Principal investigator of clinical trial

  • Dr Umberto VITOLO
  • S.C. di Ematologia
  • Dipartimento di Scienze Pediatriche e dell'Adolescenza
  • A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
  • Corso Bramante 88/90
  • 10126 TORINO
  • ITALY
  • More information
  • Phone  : 39 011 6335550
  • Fax  : -
  • Website
  • Contact secretary  :
Last update: September 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.